{
    "id": 707,
    "name": "B-cell lymphoma",
    "source": "DOID",
    "definition": "A non-Hodgkin lymphoma that has_material_basis_in B cells. [url:http\\://en.wikipedia.org/wiki/B-cell_lymphoma]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:707",
    "evidence": [
        {
            "id": 2469,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with IMO-8400 resulted in decreased survival of B-cell lymphoma cell lines harboring MYD88 L265P in culture, and decreased tumor growth in a MYD88 L265P-positive B-cell lymphoma cell line xenograft models (Cancer Res October 1, 2014 74:2570).",
            "molecularProfile": {
                "id": 6507,
                "profileName": "MYD88 L265P"
            },
            "therapy": {
                "id": 2866,
                "therapyName": "IMO-8400",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3125,
                    "pubMedId": null,
                    "title": "Abstract 2570: IMO-8400, a selective antagonist of TLRs 7, 8 and 9, inhibits MYD88 L265P mutation-driven signaling and cell survival: A potential novel approach for treatment of B-cell lymphomas harboring MYD88 L265P mutation",
                    "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/2570.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4594,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, IT-901 inhibited tumor growth in Epstein Barr Virus-induced B-cell lymphoma xenograft models (PMID: 26744524).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3551,
                "therapyName": "IT-901",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4622,
                    "pubMedId": 26744524,
                    "title": "Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-\u03baB-Controlled Oxidative Stress Responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744524"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5172,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Imbruvica (Ibrutinib), TGR01201, and Ublituximab combination treatment resulted in complete response in 14% (1/7) and partial response in 71% of patients with relapsed B-cell lymphoas within 8 weeks of treatment (J Clin Oncol 33, 2015 (suppl; abstr 8501)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3768,
                "therapyName": "Ibrutinib + Ublituximab + Umbralisib",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4898,
                    "pubMedId": null,
                    "title": "Safety and activity of the chemotherapy-free triplet of ublituximab, TGR-1202, and ibrutinib in relapsed B-cell malignancies.",
                    "url": "http://meetinglibrary.asco.org/content/152147-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5841,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, hexamethylene bisacetamide treatment resulted in cell death in Myc over expressing B-cell lymphoma cell lines in culture, and tumor suppression and prolonged survival in xenograft models (PMID: 26941288).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 3954,
                "therapyName": "hexamethylene bisacetamide",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5180,
                    "pubMedId": 26941288,
                    "title": "Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26941288"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6515,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Istodax (romidepsin) inhibited cell survival and induced apoptosis in Myc-driven B-cell lymphoma cells in both cell culture and xenograft models (PMID: 26676759).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 1075,
                "therapyName": "Romidepsin",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5674,
                    "pubMedId": 26676759,
                    "title": "Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676759"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6516,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Farydak (panobinostat) inhibited cell survival and induced apoptosis in Myc-driven B-cell lymphoma cells in culture (PMID: 26676759).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 1080,
                "therapyName": "Panobinostat",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5674,
                    "pubMedId": 26676759,
                    "title": "Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26676759"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7815,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EZH2 Y111D conferred resistance to Tazemetostat (EPZ-6438) when occurring in the same allele as EZH2 A677G in B-cell lymphoma cells in culture (PMID: 26360609).",
            "molecularProfile": {
                "id": 26052,
                "profileName": "EZH2 Y111D EZH2 A677G"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6504,
                    "pubMedId": 26360609,
                    "title": "Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26360609"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7817,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EZH2 Y111D conferred resistance to GSK126 when occurred in the same allele as EZH2 A677G in B-cell lymphoma cells in culture (PMID: 26360609).",
            "molecularProfile": {
                "id": 26052,
                "profileName": "EZH2 Y111D EZH2 A677G"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6504,
                    "pubMedId": 26360609,
                    "title": "Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26360609"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8850,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, KTE-C19 treatment resulted in complete response in 67% (2/3) and partial response in 33% (1/3) of evaluable patients with refractory aggressive B-cell non-Hodgkin lymphoma after 1 month of treatment (Blood 2015 126:3991).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4829,
                "therapyName": "KTE-C19",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6768,
                    "pubMedId": null,
                    "title": "Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)",
                    "url": "http://www.bloodjournal.org/content/126/23/3991"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12246,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial supporting FDA approval, Yescarta (KTE-C19) treatment resulted in an objective response rate of 82% (92/110), with complete response in 54% (60/110) and partial response in 28% (31/110) of patients with refractory B-cell non-Hodgkin lymphoma (Cancer Res 2017;77(13 Suppl):Abstract nr CT019).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4829,
                "therapyName": "KTE-C19",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10205,
                    "pubMedId": null,
                    "title": "Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL)",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/CT019"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9878,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, HMPL-523 decreased viability of SYK-dysregulated B-cell lymphoma cell lines in culture, and inhibited tumor growth in xenograft models (Blood Dec 2016, 128 (22) 3970).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5279,
                "therapyName": "HMPL-523",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7733,
                    "pubMedId": null,
                    "title": "HMPL-523, a Novel SYK Inhibitor Showed Anti-Tumor Activities In Vitro and In Vivo",
                    "url": "http://www.bloodjournal.org/content/128/22/3970?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9887,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rapamune (sirolimus) enhanced the efficacy of Ontak (denileukin diftitox) in human B-cell lymphoma cells, resulting in decreased cell viability in culture (PMID: 27737881).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5283,
                "therapyName": "Denileukin diftitox + Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7744,
                    "pubMedId": 27737881,
                    "title": "Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27737881"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9888,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Torisel (temsirolimus) enhanced the efficacy of Ontak (denileukin diftitox) in human B-cell lymphoma cells, resulting in decreased cell viability in culture (PMID: 27737881).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5284,
                "therapyName": "Denileukin diftitox + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7744,
                    "pubMedId": 27737881,
                    "title": "Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27737881"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9956,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAP1-null B-cell lymphoma cells demonstrated increased sensitivity to Lynparza (olaparib) in culture (PMID: 24347639).",
            "molecularProfile": {
                "id": 10247,
                "profileName": "BAP1 loss"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7819,
                    "pubMedId": 24347639,
                    "title": "Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24347639"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10441,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Alisertib (MLN8237) treatment resulted in significant toxicity and an objective response rate of 15% (2/13) in patients with B-cell non Hodgkin's lymphoma (PMID: 28278718).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8457,
                    "pubMedId": 28278718,
                    "title": "A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28278718"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11416,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, JCAR017 treatment resulted in a response rate of 80% (22/28) with a complete response rate of 60% (17/28) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (J Clin Oncol 35, 2017 (suppl; abstr 7513); NCT02631044).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5980,
                "therapyName": "JCAR017",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9301,
                    "pubMedId": null,
                    "title": "CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001).",
                    "url": "http://abstracts.asco.org/199/AbstView_199_185939.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11793,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Fenretinide treatment resulted in stable disease in a patient with B-cell lymphoma (PMID: 28420721).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2731,
                "therapyName": "Fenretinide",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9767,
                    "pubMedId": 28420721,
                    "title": "Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28420721"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13151,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, CPI-1205 treatment resulted in complete response in 3% (1/32), and stable disease in 16% (5/32) of patients with B-cell lymphomas (Annals of Oncology, Volume 29, Issue suppl_3, 1 March 2018, abstract 420; NCT02395601).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2733,
                "therapyName": "CPI-1205",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10994,
                    "pubMedId": null,
                    "title": "A phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas",
                    "url": "https://academic.oup.com/annonc/article/29/suppl_3/mdy048.001/4917513"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14096,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SKLB-23bb treatment inhibited tumor growth in B-cell lymphoma xenograft models (PMID: 29610282).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7019,
                "therapyName": "SKLB-23bb",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11452,
                    "pubMedId": 29610282,
                    "title": "SKLB-23bb, A HDAC6-Selective Inhibitor, Exhibits Superior and Broad-Spectrum Antitumor Activity via Additionally Targeting Microtubules.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29610282"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15000,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Loncastuximab tesirine treatment demonstrated safety and preliminary efficacy, resulted in an overall response rate of 59.4% (41/69, 28 complete response, 13 partial response) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, with median duration of response, progression-free survival, and overall survival of 4.8, 5.5, and 11.6 months, respectively (PMID: 31685491; NCT02669017).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7372,
                "therapyName": "Loncastuximab tesirine",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17545,
                    "pubMedId": 31685491,
                    "title": "A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31685491"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15005,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Betalutin demonstrated safety and preliminary efficacy, resulted in partial remission in 43% (3/7) and complete remission in 29% (2/7) of patients with relapsed CD37-positive non-Hodgkin's B Cell Lymphoma (Blood 2014 124(21):3094).",
            "molecularProfile": {
                "id": 30535,
                "profileName": "CD37 positive"
            },
            "therapy": {
                "id": 7393,
                "therapyName": "Betalutin",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12070,
                    "pubMedId": null,
                    "title": "A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma",
                    "url": "http://www.bloodjournal.org/content/124/21/3094?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15114,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, B-cell lymphoma cell lines with high expression of FGR were resistant to Zolinza (vorinostat) in culture (PMID: 27324824).",
            "molecularProfile": {
                "id": 30753,
                "profileName": "FGR over exp"
            },
            "therapy": {
                "id": 1077,
                "therapyName": "Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12669,
                    "pubMedId": 27324824,
                    "title": "A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27324824"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15408,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with XmAb13676 led to T-cell activation, subsequently resulting in a 97% decrease of CD40 positive B cells in circulation and a 90% reduction in lymph nodes and bone marrow in in vivo models (Blood 2014 124:3111).",
            "molecularProfile": {
                "id": 31011,
                "profileName": "CD40 positive"
            },
            "therapy": {
                "id": 7600,
                "therapyName": "XmAb13676",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13137,
                    "pubMedId": null,
                    "title": "Immunotherapy with Long-Lived Anti-CD20 \u00d7 Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human B Cell Lines and of Circulating and Lymphoid B Cells in Monkeys: A Potential Therapy for B Cell Lymphomas and Leukemias",
                    "url": "http://www.bloodjournal.org/content/124/21/3111?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15491,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Alisertib (MLN8237) in combination with Rituxan (rituximab) demonstrated safety and efficacy, resulted in an objective response rate of 25% (3/12, 2 complete response, 1 partial response), and stable disease in 42% (5/12) of patients with relapsed or refractory B-cell non-Hodgkin lymphomas (PMID: 30082475; NCT01397825).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7640,
                "therapyName": "Alisertib + Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 13343,
                    "pubMedId": 30082475,
                    "title": "Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30082475"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15492,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Alisertib (MLN8237) in combination with Rituxan (rituximab) and Oncovin (vincristine) demonstrated safety and efficacy, resulted in an objective response rate of 38% (14/37, 7 complete response, 7 partial response), and stable disease in 32% (12/37) of patients with relapsed or refractory B-cell non-Hodgkin lymphomas (PMID: 30082475; NCT01397825).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7641,
                "therapyName": "Alisertib + Rituximab + Vincristine",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 13343,
                    "pubMedId": 30082475,
                    "title": "Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30082475"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16220,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, CD70-positive patients with either diffuse large B-cell lymphoma or mantle cell lymphoma demonstrated an objective response rate of 20% (4/20) when treated with SGN-CD70A, including a complete response in one patient and a partial response in three patients, and six patients experienced stable disease (PMID: 30132271; NCT02216890).",
            "molecularProfile": {
                "id": 28616,
                "profileName": "CD70 positive"
            },
            "therapy": {
                "id": 7942,
                "therapyName": "SGN-CD70A",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14343,
                    "pubMedId": 30132271,
                    "title": "A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30132271"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16621,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JSH-150 inhibited proliferation of a B-cell lymphoma cell line in culture (PMID: 30253346).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8108,
                "therapyName": "JSH-150",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14640,
                    "pubMedId": 30253346,
                    "title": "Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30253346"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17576,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BCL2 G101V conferred resistance to BCL201 (S55746) in cultured B-cells (PMID: 31160589).",
            "molecularProfile": {
                "id": 31579,
                "profileName": "BCL2 G101V"
            },
            "therapy": {
                "id": 6414,
                "therapyName": "BCL201",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15287,
                    "pubMedId": 31160589,
                    "title": "Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31160589"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19428,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CP-870,893 treatment delayed and inhibited tumor growth, and delayed mortality in cell line xenograft models of CD40-positive B-cell lymphoma (PMID: 21479995).",
            "molecularProfile": {
                "id": 31011,
                "profileName": "CD40 positive"
            },
            "therapy": {
                "id": 9010,
                "therapyName": "CP-870,893",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17015,
                    "pubMedId": 21479995,
                    "title": "The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21479995"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19451,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WM-8014 inhibited proliferation of a mouse B-cell lymphoma cell line in culture (PMID: 30069049).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9048,
                "therapyName": "WM-8014",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17087,
                    "pubMedId": 30069049,
                    "title": "Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30069049"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19452,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WM-1119 inhibited proliferation of a mouse B-cell lymphoma cell line in culture, and induced tumor growth arrest and decreased tumor burden in mouse models (PMID: 30069049).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9049,
                "therapyName": "WM-1119",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17087,
                    "pubMedId": 30069049,
                    "title": "Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30069049"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19453,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nutlin-3 induced death of a mouse B-cell lymphoma cell line isolated from a tumor over expressing MYC in culture (PMID: 30069049).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17087,
                    "pubMedId": 30069049,
                    "title": "Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30069049"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19561,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tazemetostat (EPZ-6438) demonstrated safety and preliminary efficacy, resulted in an objective response in 38% (8/21, 3 complete response, 5 partial response) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (PMID: 29650362; NCT01897571).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17176,
                    "pubMedId": 29650362,
                    "title": "Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650362"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19702,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, GSK126 was tolerated and demonstrated preliminary efficacy, resulted in partial response in 2% (1/41) and stable disease in 34% (14/41) of patients with advanced solid tumor (n=21) or B-cell lymphoma (n=20) (PMID: 31471312; NCT02082977).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17510,
                    "pubMedId": 31471312,
                    "title": "Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31471312"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20318,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, B-cell lymphoma cell lines harboring XPO1 E571K were sensitive to treatment with Xpovio (selinexor) in culture, and in cell line xenograft models, resulting in improved survival (PMID: 31285298).",
            "molecularProfile": {
                "id": 27906,
                "profileName": "XPO1 E571K"
            },
            "therapy": {
                "id": 1749,
                "therapyName": "Selinexor",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17771,
                    "pubMedId": 31285298,
                    "title": "Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285298"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01084252",
            "title": "Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6331,
                    "therapyName": "Isatuximab",
                    "synonyms": null
                },
                {
                    "id": 6357,
                    "therapyName": "Dexamethasone + Isatuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01109069",
            "title": "Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01193842",
            "title": "Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1077,
                    "therapyName": "Vorinostat",
                    "synonyms": null
                },
                {
                    "id": 3395,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01307267",
            "title": "A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 6111,
                    "therapyName": "Rituximab + Utomilumab",
                    "synonyms": null
                },
                {
                    "id": 5086,
                    "therapyName": "Utomilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01695941",
            "title": "Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3581,
                    "therapyName": "Alisertib + Bortezomib + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01742988",
            "title": "Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8587,
                    "therapyName": "Bendamustine + CUDC-907 + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 4447,
                    "therapyName": "CUDC-907 + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 709,
                    "therapyName": "CUDC-907",
                    "synonyms": null
                },
                {
                    "id": 8586,
                    "therapyName": "CUDC-907 + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01799889",
            "title": "A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2522,
                    "therapyName": "Entospletinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01859819",
            "title": "Treatment for Advanced B-Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6875,
                    "therapyName": "Cytarabine + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01976585",
            "title": "In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4337,
                    "therapyName": "CDX-301 + Poly ICLC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02006485",
            "title": "Ublituximab in Combination With TGR-1202 in Patients With B-cell Malignancies",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2319,
                    "therapyName": "Ublituximab + Umbralisib",
                    "synonyms": null
                },
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02018861",
            "title": "A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2406,
                    "therapyName": "Itacitinib",
                    "synonyms": null
                },
                {
                    "id": 3097,
                    "therapyName": "Itacitinib + Parsaclisib",
                    "synonyms": null
                },
                {
                    "id": 1231,
                    "therapyName": "Bendamustine",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 2352,
                    "therapyName": "Carboplatin + Etoposide + Ifosfamide",
                    "synonyms": null
                },
                {
                    "id": 3088,
                    "therapyName": "Parsaclisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02106091",
            "title": "Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 7390,
                    "therapyName": "AFM11",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02153580",
            "title": "Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1136,
                    "therapyName": "Etoposide",
                    "synonyms": null
                },
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 1231,
                    "therapyName": "Bendamustine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02199184",
            "title": "Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9013,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Ofatumumab + Prednisone + Vincristine",
                    "synonyms": "DA-EPOCH + Ofatumumab"
                },
                {
                    "id": 8510,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine",
                    "synonyms": "DA-EPOCH-R"
                }
            ]
        },
        {
            "nctId": "NCT02207062",
            "title": "Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02213913",
            "title": "Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1164,
                    "therapyName": "Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 8510,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine",
                    "synonyms": "DA-EPOCH-R"
                }
            ]
        },
        {
            "nctId": "NCT02253992",
            "title": "Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2567,
                    "therapyName": "Nivolumab + Urelumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02254772",
            "title": "TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3848,
                    "therapyName": "Ipilimumab + SD-101",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02266147",
            "title": "Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3084,
                    "therapyName": "SD-101",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02272686",
            "title": "Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02290951",
            "title": "A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6151,
                    "therapyName": "REGN1979",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02328014",
            "title": "ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3265,
                    "therapyName": "ACP-319",
                    "synonyms": null
                },
                {
                    "id": 1605,
                    "therapyName": "Acalabrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02343120",
            "title": "Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2544,
                    "therapyName": "Zanubrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02395601",
            "title": "A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2733,
                    "therapyName": "CPI-1205",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02436707",
            "title": "Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                },
                {
                    "id": 3391,
                    "therapyName": "Cisplatin + Dexamethasone + Gemcitabine + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02443077",
            "title": "Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 3359,
                    "therapyName": "Carmustine + Cytarabine + Etoposide + Melphalan",
                    "synonyms": null
                },
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02500407",
            "title": "A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6305,
                    "therapyName": "Atezolizumab + BTCT4465A",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02543879",
            "title": "Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 7335,
                    "therapyName": "FT-1101",
                    "synonyms": null
                },
                {
                    "id": 7336,
                    "therapyName": "Azacitidine + FT-1101",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02569476",
            "title": "BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4682,
                    "therapyName": "Obinutuzumab + Zanubrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02600897",
            "title": "A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4394,
                    "therapyName": "Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02611323",
            "title": "A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4227,
                    "therapyName": "Obinutuzumab + Polatuzumab vedotin-piiq + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02624986",
            "title": "A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 4393,
                    "therapyName": "Idasanutlin + Obinutuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02628405",
            "title": "R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6747,
                    "therapyName": "Carboplatin + Etoposide + Ifosfamide + Lenalidomide + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02631044",
            "title": "Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5980,
                    "therapyName": "JCAR017",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02693535",
            "title": "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                },
                {
                    "id": 682,
                    "therapyName": "Talazoparib",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                },
                {
                    "id": 1389,
                    "therapyName": "Pertuzumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 706,
                    "therapyName": "Crizotinib",
                    "synonyms": null
                },
                {
                    "id": 802,
                    "therapyName": "Abemaciclib",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02706405",
            "title": "JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4365,
                    "therapyName": "Cyclophosphamide + Durvalumab + JCAR014",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02715843",
            "title": "Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma",
            "phase": "Expanded access",
            "recruitment": "No longer available",
            "therapies": [
                {
                    "id": 7831,
                    "therapyName": "MT-3724",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02733042",
            "title": "A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 4278,
                    "therapyName": "Durvalumab + Lenalidomide + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 4279,
                    "therapyName": "Bendamustine + Durvalumab + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 2573,
                    "therapyName": "Durvalumab + Ibrutinib",
                    "synonyms": null
                },
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02846935",
            "title": "p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies",
            "phase": "Phase 0",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3567,
                    "therapyName": "Decitabine + Tetrahydrouridine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02875002",
            "title": "Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4826,
                    "therapyName": "Belinostat + Volasertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02898259",
            "title": "Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6933,
                    "therapyName": "Ixazomib + Lenalidomide + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02914938",
            "title": "A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6745,
                    "therapyName": "ME-401",
                    "synonyms": null
                },
                {
                    "id": 6746,
                    "therapyName": "ME-401 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02924402",
            "title": "Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7600,
                    "therapyName": "XmAb13676",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02950220",
            "title": "Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4917,
                    "therapyName": "Ibrutinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02973113",
            "title": "Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5058,
                    "therapyName": "EB-VST cells + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02992522",
            "title": "Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 5133,
                    "therapyName": "Lenalidomide + Obinutuzumab + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02997761",
            "title": "Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5125,
                    "therapyName": "Blinatumomab + Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03019640",
            "title": "Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6934,
                    "therapyName": "Carmustine + Cytarabine + Etoposide + Filgrastim + Lenalidomide + Melphalan + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03028103",
            "title": "Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5267,
                    "therapyName": "Fluconazole + Tazemetostat",
                    "synonyms": null
                },
                {
                    "id": 5285,
                    "therapyName": "Omeprazole + Repaglinide + Tazemetostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03036904",
            "title": "Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5294,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Venetoclax + Vincristine",
                    "synonyms": "Venetoclax + DA-EPOCH-R"
                }
            ]
        },
        {
            "nctId": "NCT03038672",
            "title": "Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2526,
                    "therapyName": "Nivolumab + Varlilumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03103971",
            "title": "huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9019,
                    "therapyName": "Cyclophosphamide + Fludarabine + HuJCAR014",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03133221",
            "title": "1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1023,
                    "therapyName": "Idelalisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03153462",
            "title": "Axicabtagene Ciloleucel Expanded Access Study",
            "phase": "Expanded access",
            "recruitment": "Available",
            "therapies": [
                {
                    "id": 5098,
                    "therapyName": "Cyclophosphamide + Fludarabine + KTE-C19",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03217253",
            "title": "Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 2683,
                    "therapyName": "Tazemetostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03223610",
            "title": "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6189,
                    "therapyName": "Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03274492",
            "title": "A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4226,
                    "therapyName": "Polatuzumab vedotin-piiq",
                    "synonyms": null
                },
                {
                    "id": 6177,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 2195,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Rituximab + CHOP|RCHOP"
                }
            ]
        },
        {
            "nctId": "NCT03277729",
            "title": "A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9487,
                    "therapyName": "CD20 CAR T-cells + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03310619",
            "title": "A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6910,
                    "therapyName": "Durvalumab + JCAR017",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03328078",
            "title": "A Study of CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7396,
                    "therapyName": "CA-4948",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03410901",
            "title": "TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6935,
                    "therapyName": "BMS-986178 + SD-101",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03424603",
            "title": "Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7413,
                    "therapyName": "STRO-001",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03483103",
            "title": "Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5980,
                    "therapyName": "JCAR017",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03488251",
            "title": "PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7992,
                    "therapyName": "Gemcitabine + MT-3724 + Oxaliplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03570892",
            "title": "Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1164,
                    "therapyName": "Lenalidomide",
                    "synonyms": null
                },
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                },
                {
                    "id": 3360,
                    "therapyName": "Carboplatin + Etoposide + Ifosfamide + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 3359,
                    "therapyName": "Carmustine + Cytarabine + Etoposide + Melphalan",
                    "synonyms": null
                },
                {
                    "id": 3391,
                    "therapyName": "Cisplatin + Dexamethasone + Gemcitabine + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 7940,
                    "therapyName": "Cyclophosphamide + Fludarabine + Tisagenlecleucel",
                    "synonyms": null
                },
                {
                    "id": 6725,
                    "therapyName": "Cisplatin + Cytarabine + Dexamethasone + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 5090,
                    "therapyName": "Gemcitabine + Oxaliplatin + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 8370,
                    "therapyName": "Bendamustine + Fludarabine + Tisagenlecleucel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03573310",
            "title": "A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9749,
                    "therapyName": "JNJ-64619178",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03579927",
            "title": "CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                },
                {
                    "id": 6213,
                    "therapyName": "iC9/CAR.19/IL15-Transduced CB-NK",
                    "synonyms": null
                },
                {
                    "id": 7797,
                    "therapyName": "Carmustine + Cytarabine + Etoposide + Melphalan + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03589469",
            "title": "Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7372,
                    "therapyName": "Loncastuximab tesirine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03605589",
            "title": "Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5839,
                    "therapyName": "Blinatumomab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03645395",
            "title": "PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8222,
                    "therapyName": "Lenalidomide + MT-3724",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03684980",
            "title": "LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma - ARM A",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9622,
                    "therapyName": "Glucarpidase + Leucovorin + Methotrexate + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03696784",
            "title": "Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5992,
                    "therapyName": "Rimiducid",
                    "synonyms": null
                },
                {
                    "id": 7976,
                    "therapyName": "Bendamustine + Fludarabine + iC9/CAR.19/IL15-Transduced CB-NK",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03704298",
            "title": "Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma (ZUMA-11)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7949,
                    "therapyName": "KTE-C19 + Utomilumab",
                    "synonyms": null
                },
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03704714",
            "title": "Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7718,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Nivolumab + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Nivolumab + Rituximab + CHOP"
                }
            ]
        },
        {
            "nctId": "NCT03742258",
            "title": "Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7648,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + TAK-659 + Vincristine",
                    "synonyms": "Rituximab + TAK-659 + CHOP"
                },
                {
                    "id": 2195,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Rituximab + CHOP|RCHOP"
                }
            ]
        },
        {
            "nctId": "NCT03749018",
            "title": "Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7726,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Nivolumab + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Nivolumab + R-EPOCH"
                }
            ]
        },
        {
            "nctId": "NCT03761056",
            "title": "Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (ZUMA-12)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5098,
                    "therapyName": "Cyclophosphamide + Fludarabine + KTE-C19",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03793140",
            "title": "A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6992,
                    "therapyName": "CPI-613",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03920631",
            "title": "Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03934814",
            "title": "Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8233,
                    "therapyName": "TJ011133",
                    "synonyms": null
                },
                {
                    "id": 8235,
                    "therapyName": "Pembrolizumab + TJ011133",
                    "synonyms": null
                },
                {
                    "id": 8234,
                    "therapyName": "Rituximab + TJ011133",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03990961",
            "title": "Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03995147",
            "title": "Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8497,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Pembrolizumab + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Pembrolizumab + R-CHOP"
                }
            ]
        },
        {
            "nctId": "NCT04023071",
            "title": "FT516 in Subjects With Advanced Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9136,
                    "therapyName": "Aldesleukin + Cyclophosphamide + Fludarabine + FT516 + Obinutuzumab",
                    "synonyms": null
                },
                {
                    "id": 9135,
                    "therapyName": "Aldesleukin + Cyclophosphamide + Fludarabine + FT516 + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 9133,
                    "therapyName": "Aldesleukin + Cyclophosphamide + Fludarabine + FT516",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04045028",
            "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4268,
                    "therapyName": "MTIG7192A",
                    "synonyms": null
                },
                {
                    "id": 9143,
                    "therapyName": "Daratumumab + MTIG7192A",
                    "synonyms": null
                },
                {
                    "id": 9144,
                    "therapyName": "MTIG7192A + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04074330",
            "title": "A Study of TAK-981 in Combination With Rituximab in Participants With Relapsed/Refractory (r/r) CD20-positive (CD20+) Non-Hodgkin Lymphoma (NHL)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9146,
                    "therapyName": "Rituximab + TAK-981",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04074746",
            "title": "Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8710,
                    "therapyName": "AFM13 + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04160195",
            "title": "T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 8529,
                    "therapyName": "Anti-CD19/CD20 CAR T cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04170283",
            "title": "Long-term Extension Study of Zanubrutinib (BGB-3111) in Patients With B-cell Malignancies",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2544,
                    "therapyName": "Zanubrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04205838",
            "title": "Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9784,
                    "therapyName": "Anakinra + Cyclophosphamide + Fludarabine + KTE-C19",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04214886",
            "title": "CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9728,
                    "therapyName": "CD19-CD34 CAR transduced T cells + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04220008",
            "title": "Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9202,
                    "therapyName": "Busulfan + Clofarabine + Cyclophosphamide + Gemcitabine + Mycophenolate mofetil + Rituximab + Tacrolimus + Vorinostat",
                    "synonyms": null
                },
                {
                    "id": 9201,
                    "therapyName": "Busulfan + Clofarabine + Cyclophosphamide + Gemcitabine + Mycophenolate mofetil + Tacrolimus + Vorinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04231747",
            "title": "A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9650,
                    "therapyName": "CC-97540",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04231877",
            "title": "Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9654,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Polatuzumab vedotin-piiq + Prednisone + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04245722",
            "title": "FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9626,
                    "therapyName": "Cyclophosphamide + Fludarabine + FT596 + Obinutuzumab",
                    "synonyms": null
                },
                {
                    "id": 9624,
                    "therapyName": "Cyclophosphamide + Fludarabine + FT596",
                    "synonyms": null
                },
                {
                    "id": 9625,
                    "therapyName": "Cyclophosphamide + Fludarabine + FT596 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04257578",
            "title": "Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9318,
                    "therapyName": "Acalabrutinib + KTE-C19",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04285268",
            "title": "Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9428,
                    "therapyName": "Bortezomib + Rituximab + Venetoclax",
                    "synonyms": null
                }
            ]
        }
    ]
}